Drug intelligence / Profile preview

tenatoprazole

Development stage: Unknown
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

Tenatoprazole is a proton pump inhibitor (PPI) drug candidate developed by Mitsubishi Tanabe Pharma. It was designed to treat conditions like reflux oesophagitis and peptic ulcers. Tenatoprazole has an imidazopyridine ring instead of the benzimidazole moiety found in other PPIs, giving it a longer half-life compared to other drugs in its class. It works by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby reducing stomach acid secretion.

Other names: benatoprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on tenatoprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenatoprazole.

Explore the full profile